Navigation Links
AEterna Zentaris Announces Changes to its Management Team
Date:4/11/2008

ent to explore other such opportunities with a view to identifying additional non-core assets as a further potential source of non-dilutive funding.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
(Date:7/30/2014)... 30, 2014 Selexis SA , ... drug discovery and mammalian cell line development, announced today ... ™ will be presented at the 10th Annual ... September 8 – 10, 2014 at the Double Tree ... The following abstract will be presented during an oral ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... of Spinal Muscular Atrophy SOUTH PLAINFIELD, N.J. and NEW ... the Spinal Muscular Atrophy (SMA) Foundation today announced the ... Foundation will provide up to $8.5 million in funding ... the collaboration to fund a series of research projects ...
... 12 NovImmune, an,immunology-focused biotech company dedicated to ... it has raised CHF,62.5 million (USD 54.8 million) ... and NI-0501, a fully human monoclonal antibody to ... its pipeline.,The transaction was led by BZ Bank ...
... (Nasdaq: VRUS ), a clinical stage pharmaceutical ... to treat viral infections, reported financial results and operational ... Financial Results Revenues were $1.9 million during the ... for the quarter ended March 31, 2008 and reflect ...
Cached Biology Technology:PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 3NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 3Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 4Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 5Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 6Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 7Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 8
(Date:7/31/2014)... cells, are inherently different. Each of these cell types ... in metabolism. In the human body, white adipose tissue ... is energy storage. On the other hand, brown adipocytes ... found in a few places in the adult human ... brown adipocytes, appear mixed with brown adipocytes in human ...
(Date:7/31/2014)... shown that marine noise can affect animal movement and ... of Bristol and Exeter and the cole Pratique des ... boat noise stops embryonic development and increases larval mortality ... slug Stylocheilus striatus used in this study) ... later feed on toxic alga but this study, conducted ...
(Date:7/30/2014)... regulate its genes, and adapt to changes in its ... regulation taking place in the truffle, is published in ... illustrates how the truffle deals with its complex genome,s ... may shed light on how traits like aroma and ... known as Prigord truffles, have a syrupy sweet flavor ...
Breaking Biology News(10 mins):Hope for the overweight 2Boat noise impacts development and survival of sea hares 2How black truffles deal with the jumpers in their genome 2
... The next generation of biometric technology launches today with ... by University of Toronto engineering graduates. The Nymi is ... unique heartbeat to unlock your identity. The convenient and ... sensor. When the Nymi recognizes your personal ECG, it ...
... American Association of Pharmaceutical Scientists (AAPS) ... gather to share the latest groundbreaking scientific discoveries and ... Exposition. ,The event will bring together more than 8,000 ... discuss current initiatives underway aimed at improving global health ...
... The science and engineering capabilities that underpin the ... nation,s three national security laboratories are "healthy and vibrant," ... The committee that wrote the report found no ... would prevent certification of the stockpile. However, the report ...
Cached Biology News:Nymi by Bionym launches using your unique heartbeat to unlock your world 2New report reviews science and engineering quality at national security laboratories 2
... Immunogen: Recombinant human IDO (Indoleamine-pyrrol ... the ~44 kDa human IDO ... control: IFN-Gamma-stimmulated Human peripheral blood ... reactivity with mouse and rat ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
... total protein western blot (WtPAN) ... tissue specific protein expression in ... protein is included in each ... for comparison between different western ...
Biology Products: